Search for: "Nobles v. Georgia" Results 21 - 32 of 32
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Jul 2011, 6:42 am by Ilya Shapiro - Guest
The following is an essay for our symposium on Arizona v. [read post]
23 Feb 2011, 4:02 pm by INFORRM
Problem areas include what “unaware” means, the exclusion of electronic communications such as emails and the very broad common law definition of “publication” which has not changed since Duke of Brunswick v Hamer (1849) 14 QB 185. [read post]
6 Jan 2011, 9:38 am by Kent Scheidegger
Georgia, 2 U.S. 419 (1973).The citizenship clause of the Fourteenth Amendment abrogated one of the key holdings of Scott v. [read post]
30 Nov 2010, 7:32 am by Steve Hall
That year, he famously wrote in dissent in Callins v. [read post]
28 Sep 2009, 7:30 am by Susan Schneider
As a past President of the AALA, I was honored to be seated at the head table with the Secretary and other AALA representatives.Other alumni presenters included:Terry Centner, Professor of Agricultural and Applied Economics,University of Georgia; Marne Coit, Agricultural Policy Consultant and Apple Seeds Board Member, Fayetteville, Arkansas; Janie Hipp, Director, Risk Management Education Division, USDA Risk Management Agency;Martha Noble, Senior Policy Associate with the… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
22 Mar 2008, 2:00 am
: (IPBiz),US: Two remaining challenged WARF embryonic stem cell patents upheld in ex parte reexamination: (Holman's Biotech IP Blog), Pharma & Biotech - ProductsAricept (Donepezil) – USV wins appeal against USPTO decision: (Spicy IP),Celerex (Celecoxib) – CAFC decision in Celebrex patents dispute between Pfizer and Teva will cut patent term by one and a half years: (Patent Baristas), Inersan – Ranbaxy in-licenses Inersan to CD Pharma to market in India and… [read post]